Grifols (GRFS) Debt to Equity (2009 - 2026)
Grifols (GRFS) debt to equity from Dec 31, 2009 to Mar 31, 2026. The current Grifols (GRFS) debt to equity is 177.15%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Grifols (GRFS)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 165.89% | -3.22% |
| 2024 | 171.42% | -16.47% |
| 2023 | 205.21% | +18.88% |
| 2022 | 172.61% | -6.21% |
| 2021 | 184.04% | +36.03% |
| 2020 | 135.30% | -8.18% |
| 2019 | 147.35% | +3.24% |
| 2018 | 142.73% | -13.83% |
| 2017 | 165.64% | +26.19% |
| 2016 | 131.27% | -9.08% |
| 2015 | 144.37% | -9.44% |
| 2014 | 159.41% | +24.55% |
| 2013 | 127.99% | -13.53% |
| 2012 | 148.02% | -16.78% |
| 2011 | 177.86% | +43.83% |
| 2010 | 123.66% | -14.29% |
| 2009 | 144.28% | +45.58% |
| 2008 | 99.11% | +1.69% |
| 2007 | 97.47% | +6.35% |
| 2006 | 91.65% | N/A |
Comparison Grifols (GRFS) debt to equity with competitors
Grifols (GRFS) debt to equity is 177.15%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| SNY | Sanofi | 27.50% | -84.48% |
| BIIB | Biogen Inc | 33.72% | -80.97% |
| JNJ | Johnson & Johnson | 67.73% | -61.77% |
| PFE | Pfizer Inc | 71.50% | -59.64% |
| AZN | Astrazeneca plc | 71.66% | -59.55% |
| NVO | Novo Nordisk | 72.09% | -59.31% |
| GILD | Gilead Sciences Inc | 94.30% | -46.77% |
| GSK | GSK Plc | 106.74% | -39.74% |
| MRK | Merck & Co Inc | 107.06% | -39.57% |
| NVS | Novartis AG | 122.03% | -31.11% |
| LLY | Lilly(Eli) & Company | 139.02% | -21.53% |
| MDCX | MDCorp | 176.75% | -0.23% |
| MDCXW | Medicus Pharma Ltd warrant | 176.75% | -0.23% |
| BMY | Bristol-Myers Squibb Company | 219.95% | +24.16% |
| AMGN | AMGEN Inc | 623.75% | +252.10% |
| OGN | Organon & Company | 948.95% | +435.67% |